Parthenon Llc Investment Activity in Q2 2026
This article summarizes observable purchases and sales by Parthenon Llc during the second quarter of 2026, based on available data.

As reported for the period ending June 30, 2026, Parthenon Llc's portfolio saw specific changes in holdings across various sectors. The analysis focuses on significant adjustments observed during this quarter.
Among the notable shifts, Booking Holdings Inc (BKNG) stands out as a new position acquired by the investor fund. This acquisition reflects an increase of 91,603 shares, representing a substantial 2412.51% change from the previous period.
In Technology, established holdings like Microsoft Corp (MSFT) and Apple Inc (AAPL) experienced minor share reductions. Microsoft saw a decrease of 0.25% in its portfolio allocation, while Apple's was slightly lower by 0.16%. However, Richardson Electronics Ltd (RELL), another Technology holding, showed significant selling pressure with an approximate 26.8% reduction in shares.
In Healthcare, both Johnson & Johnson (JNJ) and Merck & Co Inc (MRK) saw slight share decreases during the quarter. No major new purchases were indicated in this sector for Parthenon Llc.
The Consumer Defensive sector witnessed activity with Whole Foods Market (WMT) showing a small reduction of 0.45% allocation, and significant changes occurred at established consumer staples positions like Procter & Gamble Co (PG). PG experienced a notable decrease in shares held by Parthenon Llc.
Turning to Communication Services, the investor maintained significant stakes in companies like Alphabet Inc, holding both GOOGL and GOOG. However, these holdings saw share reductions of about 3.56% and 2.98%, respectively. The sector also showed a decrease in allocation for ATLANTA BRAVES HLDGS INC (BATRK).
In summary, Parthenon Llc's portfolio adjustments this quarter included new positions like BKNG, while existing holdings such as GLW and GOOGL saw reductions. The investor also disposed of some Technology shares through significant selling activity.